Date: 04 Nov 2011

“Seizing” the opportunity to understand antifibrinolytic drugs

C. David Mazer has received research funding and/or honoraria from NovoNordisk, Cubist, Bayer, The Medicines Company, Oxygen Biotherapeutics, Hemcon and AstraZeneca